Yoshikazu Sumitani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yoshikazu Sumitani has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Hitoshi Ishida
Third Department of Internal Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan
3 shared publications Susumu Nishida
3 shared publications- Atsuko Kitahara
Third Department of Internal Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan
2 shared publications Eiji Itagaki
2 shared publications- Hirohisa Onuma
Third Department of Internal Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan
2 shared publications - Kazuto Takahashi
Third Department of Internal Medicine, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan
2 shared publications
Latest Publications
- Open Access
- 20 June 2017
- Published by MDPI AG in Marine Drugs
- Vol. 15 (6) , 185
The Novel Mechanisms Concerning the Inhibitions of Palmitate-Induced Proinflammatory Factor Releases and Endogenous Cellular Stress with Astaxanthin on MIN6 β-Cells
Astaxanthin, an antioxidant agent, can protect pancreatic β-cells of db/db mice from glucotoxicity and resolve chronic inflammation in adipose tissue. Nonetheless, the effects of astaxanthin on free-fatty-acid-induced inflammation and cellular stress in β-cells remain to be demonstrated. Meanwhile, palmitate enhances the secretion of pro-inflammatory adipokines monocyte chemoattractant protein-1 (MCP-1) and vascular endothelial growth factor (VEGF120). We therefore investigated the influence of astaxanthin on palmitate-stimulated MCP-1 and VEGF120 secretion in mouse insulinoma (MIN6) pancreatic β-cells. Furthermore, whether astaxanthin prevents cellular stress in MIN6 cells was also assessed. Pre-treatment with astaxanthin or with N-acetyl-cysteine (NAC) which is an antioxidant drug, significantly attenuated the palmitate-induced MCP-1 release through downregulation of phosphorylated c-Jun NH2-terminal protein kinase (JNK) pathways, and suppressed VEGF120 through the PI3K/Akt pathways relative to the cells stimulated with palmitate alone. In addition, palmitate significantly upregulated homologous protein (CHOP) and anti-glucose-regulated protein (GRP78), which are endoplasmic reticulum (ER) stress markers, in MIN6 cells. On the other hand, astaxanthin attenuated the increased CHOP content, but further up-regulated palmitate-stimulated GRP78 protein expression. By contrast, NAC had no effects on either CHOP or GRP78 enhancement induced by palmitate in MIN6 cells. In conclusion, astaxanthin diminishes the palmitate-stimulated increase in MCP-1 secretion via the downregulation of JNK pathways in MIN6 cells, and affects VEGF120 secretion through PI3K/Akt pathways. Moreover, astaxanthin can prevent not only oxidative stress caused endogenously by palmitate but also ER stress, which NAC fails to attenuate, via upregulation of GRP78, an ER chaperon.
- 20 June 2017
- Published by MDPI AG in Marine Drugs
- Vol. 15 (6) , 185
Open AccessThe Novel Mechanisms Concerning the Inhibitions of Palmitate-Induced Proinflammatory Factor Releases and Endogenous Cellular Stress with Astaxanthin on MIN6 β-Cells
Astaxanthin, an antioxidant agent, can protect pancreatic β-cells of db/db mice from glucotoxicity and resolve chronic inflammation in adipose tissue. Nonetheless, the effects of astaxanthin on free-fatty-acid-induced inflammation and cellular stress in β-cells remain to be demonstrated. Meanwhile, palmitate enhances the secretion of pro-inflammatory adipokines monocyte chemoattractant protein-1 (MCP-1) and vascular endothelial growth factor (VEGF120). We therefore investigated the influence of astaxanthin on palmitate-stimulated MCP-1 and VEGF120 secretion in mouse insulinoma (MIN6) pancreatic β-cells. Furthermore, whether astaxanthin prevents cellular stress in MIN6 cells was also assessed. Pre-treatment with astaxanthin or with N-acetyl-cysteine (NAC) which is an antioxidant drug, significantly attenuated the palmitate-induced MCP-1 release through downregulation of phosphorylated c-Jun NH2-terminal protein kinase (JNK) pathways, and suppressed VEGF120 through the PI3K/Akt pathways relative to the cells stimulated with palmitate alone. In addition, palmitate significantly upregulated homologous protein (CHOP) and anti-glucose-regulated protein (GRP78), which are endoplasmic reticulum (ER) stress markers, in MIN6 cells. On the other hand, astaxanthin attenuated the increased CHOP content, but further up-regulated palmitate-stimulated GRP78 protein expression. By contrast, NAC had no effects on either CHOP or GRP78 enhancement induced by palmitate in MIN6 cells. In conclusion, astaxanthin diminishes the palmitate-stimulated increase in MCP-1 secretion via the downregulation of JNK pathways in MIN6 cells, and affects VEGF120 secretion through PI3K/Akt pathways. Moreover, astaxanthin can prevent not only oxidative stress caused endogenously by palmitate but also ER stress, which NAC fails to attenuate, via upregulation of GRP78, an ER chaperon.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
A case of tumor-induced osteomalacia in which recurrence and bilateral lung metastases occurred following tumor resection
A 32-year-old woman with a nine-year history of right hip pain was admitted after she became unable to walk. Based on marked hypophosphatemia as indicated by serum phosphate of 1.4 mg/dl, intactPTH;29 pg/ml, TmP/GFR;1.14 mg/dl, and fibroblast growth factor 23 (FGF23) increased to 713 pg/ml, tumor-induced osteomalacia (TIO) was diagnosed. Systemic venous sampling of FGF23 performed for locating the tumor revealed an elevated level of 1600 pg/ml in the right femoral vein, and MRI of the right leg showed a tumor 26mm in size on the dorsal side of the right knee. In June 2011, the tumor in the right knee was surgically resected. Hypophosphatemia promptly improved following surgery, and FGF23 also returned to normal. The patient became able to walk independently and was able to reintegrate into society. The pathological diagnosis was phosphaturic mesenchymal tumor. However, serum phosphate again decreased in April 2013 to 2.6 mg/dl. FGF23 also increased to 221 pg/ml. Leg MRI was performed, and a tumor 25 mm in size was again detected on the dorsal side of the right knee. FDG PET/CT revealed significant uptake that was consistent with the tumor on the dorsal side of the right knee, as well as multiple nodules seen in both lung fields on CT. The tumor in the right knee was surgically resected in September 2013. However, FGF23, which was elevated to 1500 pg/ml preoperatively, remained high postoperatively at 950 pg/ml. Hypophosphatemia also did not improve, and phosphate treatment is being continued. Because she tested positive for somatostatin receptor 2 on RT-PCR using a resected sample, treatment using a somatostatin analog is being considered. Summary: Malignant TIO is extremely rare, and no effective treatment exists for this condition. We herein report our experience with a case of malignant TIO in which recurrence and metastases to both lungs were observed two years after tumor resection.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
A case of tumor-induced osteomalacia in which recurrence and bilateral lung metastases occurred following tumor resection
A 32-year-old woman with a nine-year history of right hip pain was admitted after she became unable to walk. Based on marked hypophosphatemia as indicated by serum phosphate of 1.4 mg/dl, intactPTH;29 pg/ml, TmP/GFR;1.14 mg/dl, and fibroblast growth factor 23 (FGF23) increased to 713 pg/ml, tumor-induced osteomalacia (TIO) was diagnosed. Systemic venous sampling of FGF23 performed for locating the tumor revealed an elevated level of 1600 pg/ml in the right femoral vein, and MRI of the right leg showed a tumor 26mm in size on the dorsal side of the right knee. In June 2011, the tumor in the right knee was surgically resected. Hypophosphatemia promptly improved following surgery, and FGF23 also returned to normal. The patient became able to walk independently and was able to reintegrate into society. The pathological diagnosis was phosphaturic mesenchymal tumor. However, serum phosphate again decreased in April 2013 to 2.6 mg/dl. FGF23 also increased to 221 pg/ml. Leg MRI was performed, and a tumor 25 mm in size was again detected on the dorsal side of the right knee. FDG PET/CT revealed significant uptake that was consistent with the tumor on the dorsal side of the right knee, as well as multiple nodules seen in both lung fields on CT. The tumor in the right knee was surgically resected in September 2013. However, FGF23, which was elevated to 1500 pg/ml preoperatively, remained high postoperatively at 950 pg/ml. Hypophosphatemia also did not improve, and phosphate treatment is being continued. Because she tested positive for somatostatin receptor 2 on RT-PCR using a resected sample, treatment using a somatostatin analog is being considered. Summary: Malignant TIO is extremely rare, and no effective treatment exists for this condition. We herein report our experience with a case of malignant TIO in which recurrence and metastases to both lungs were observed two years after tumor resection.
- 26 October 2015
- Published by Springer Nature in Diabetology International
- Vol. 7 (3) , 228-234
Clinical effect of real time pulse rate monitoring with a portable pulsimeter on physical exercise therapy for male patients with type 2 diabetes
In patients with type 2 diabetes, it is recommended that exercise therapy is performed using heart rate as an index of exercise intensity. This study was designed to clinically evaluate whether continuous exercise therapy with a portable pulsimeter for self-monitoring of the pulse rate influences glycemic control in patients with type 2 diabetes. We randomly assigned 23 male patients to a pulse displayed group (in which the portable pulsimeter displayed a pulse rate) or a pulse non-displayed group (in which the portable pulsimeter only recorded the data and did not display a pulse rate). The patients then received exercise therapy for 1 month. Patients in the pulse displayed group were instructed to regulate their walking speed by maintaining their portable pulsimeter in the target pulse rate zone, whereas patients in the pulse non-displayed group were instructed to regulate their walking speed while taking their pulse rate and using the Borg scale to maintain the target pulse rate zone using the conventional method. We found the mean walking time within the target pulse rate zone during exercise therapy was significantly increased in the pulse displayed group (p < 0.01). Similarly, glycoalbumin and 1,5-anhydro-D-glucitol improved significantly in the pulse displayed group after 1 month of exercise therapy (p < 0.01, respectively). Our results suggest that this therapeutic device might be useful for improving glycemic control in patients with type 2 diabetes.
- 26 October 2015
- Published by Springer Nature in Diabetology International
- Vol. 7 (3) , 228-234
Clinical effect of real time pulse rate monitoring with a portable pulsimeter on physical exercise therapy for male patients with type 2 diabetes
In patients with type 2 diabetes, it is recommended that exercise therapy is performed using heart rate as an index of exercise intensity. This study was designed to clinically evaluate whether continuous exercise therapy with a portable pulsimeter for self-monitoring of the pulse rate influences glycemic control in patients with type 2 diabetes. We randomly assigned 23 male patients to a pulse displayed group (in which the portable pulsimeter displayed a pulse rate) or a pulse non-displayed group (in which the portable pulsimeter only recorded the data and did not display a pulse rate). The patients then received exercise therapy for 1 month. Patients in the pulse displayed group were instructed to regulate their walking speed by maintaining their portable pulsimeter in the target pulse rate zone, whereas patients in the pulse non-displayed group were instructed to regulate their walking speed while taking their pulse rate and using the Borg scale to maintain the target pulse rate zone using the conventional method. We found the mean walking time within the target pulse rate zone during exercise therapy was significantly increased in the pulse displayed group (p < 0.01). Similarly, glycoalbumin and 1,5-anhydro-D-glucitol improved significantly in the pulse displayed group after 1 month of exercise therapy (p < 0.01, respectively). Our results suggest that this therapeutic device might be useful for improving glycemic control in patients with type 2 diabetes.
- 1 March 2014
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 445 (2) , 275-281
Possible involvement of PI3K-dependent pathways in the increased VEGF120 release from osteoblastic cells preloaded with palmitate in vitro
- 1 March 2014
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 445 (2) , 275-281
Possible involvement of PI3K-dependent pathways in the increased VEGF120 release from osteoblastic cells preloaded with palmitate in vitro